50% OFF
MarketBeat All Access
Get 30 days free. Save 50% your first year.
  •  days
  •  Hours
  •  Minutes
  •  Seconds
×
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Alzheimer's drug shows promise in early results of study
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Asian stocks follow Wall St. higher after UK calms markets
Can United Natural Foods Fight Both Inflation and the Fed?
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Alzheimer's drug shows promise in early results of study
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Asian stocks follow Wall St. higher after UK calms markets
Can United Natural Foods Fight Both Inflation and the Fed?
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Alzheimer's drug shows promise in early results of study
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Asian stocks follow Wall St. higher after UK calms markets
Can United Natural Foods Fight Both Inflation and the Fed?
S&P 500   3,719.04
DOW   29,683.74
QQQ   279.94
Mullen Automotive Is Ready To Get In Gear
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
You Don't Have to Go It Alone. It's Time to Let Go and Let Others Help.
Cracker Barrel: A Tasty Treat Or Bad Apple? 
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Alzheimer's drug shows promise in early results of study
This Little Known Small Cap Is Up 139%: Is The Stock A Buy?
Biden Warns: China Could "Eat Our Lunch" When it Comes to Lithium (Ad)
Asian stocks follow Wall St. higher after UK calms markets
Can United Natural Foods Fight Both Inflation and the Fed?
NYSE:SNN

Smith & Nephew - SNN Stock Forecast, Price & News

$22.63
+0.68 (+3.10%)
(As of 09/28/2022 12:00 AM ET)
Add
Compare
Today's Range
$21.95
$22.72
50-Day Range
$21.95
$29.35
52-Week Range
$21.77
$37.28
Volume
1.29 million shs
Average Volume
1.69 million shs
Market Capitalization
$9.85 billion
P/E Ratio
N/A
Dividend Yield
4.12%
Price Target
N/A

Smith & Nephew MarketRank™ Forecast

Analyst Rating
N/A
Upside/​Downside
N/A
Short Interest
Healthy
0.87% of Float Sold Short
Dividend Strength
Moderate
Based on Four Factors
Sustainability
N/A
News Sentiment
-0.04mentions of Smith & Nephew in the last 14 days
Based on 5 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
12.10%
From $1.57 to $1.76 Per Share

Overall MarketRank

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.51 out of 5 stars

Medical Sector

1026th out of 1,096 stocks

Surgical Appliances & Supplies Industry

22nd out of 24 stocks

SNN stock logo

About Smith & Nephew (NYSE:SNN) Stock

Smith & Nephew plc, together with its subsidiaries, develops, manufactures, markets, and sells medical devices worldwide. The company offers knee implant products for knee replacement procedures; hip implants for the reconstruction of hip joints; and trauma and extremities products that include internal and external devices used in the stabilization of severe fractures and deformity correction procedures. It also provides sports medicine joint repair products for surgeons, including instruments, technologies, and implants necessary to perform minimally invasive surgery of the joints, such as the repair of soft tissue injuries and degenerative conditions of the knee, hip, and shoulder, as well as meniscal repair systems. In addition, the company offers arthroscopic enabling technologies comprising fluid management equipment for surgical access, high-definition cameras, digital image capture, scopes, light sources, and monitors to assist with visualization inside the joints, radio frequency, electromechanical and mechanical tissue resection devices, and hand instruments for removing damaged tissue; and ear, nose, and throat solutions. Further, it provides advanced wound care products for the treatment and prevention of acute and chronic wounds, which comprise leg, diabetic and pressure ulcers, burns, and post-operative wounds; advanced wound bioactives, including biologics and other bioactive technologies for debridement and dermal repair/regeneration, as well as regenerative medicine products including skin, bone graft, and articular cartilage substitutes; and advanced wound devices, such as traditional and single-use negative pressure wound therapy, and hydrosurgery systems. It primarily serves the healthcare providers. Smith & Nephew plc was founded in 1856 and is headquartered in Watford, the United Kingdom.

Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SNN Stock News Headlines

Brokerages Set Smith & Nephew plc (NYSE:SNN) PT at $1,396.00
Smith & Nephew: Still A Buy Despite Short-Term Challenges
Smith & Nephew (NYSE:SNN) Reaches New 52-Week Low at $23.47
Smith & Nephew reports Q1 results
Top investment tips for a stocks and shares ISA
See More Headlines
Receive SNN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Smith & Nephew and its competitors with MarketBeat's FREE daily newsletter.

SNN Company Calendar

Last Earnings
11/17/2014
Today
9/29/2022
Ex-Dividend for 10/26 Dividend
9/29/2022
Dividend Payable
10/26/2022
Fiscal Year End
12/31/2022

Industry, Sector and Symbol

Industry
Surgical appliances & supplies
Sub-Industry
N/A
Sector
Medical
Employees
18,000
Year Founded
1856

Profitability

Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
$5.21 billion
Cash Flow
$2.99 per share
Book Value
$12.66 per share

Miscellaneous

Free Float
430,951,000
Market Cap
$9.85 billion
Optionable
Optionable
Beta
0.62

Social Links


Key Executives

  • Ms. Anne-Francoise Nesmes (Age 50)
    CFO & Exec. Director
    Comp: $1.71M
  • Dr. Deepak S. Nath Ph.D. (Age 49)
    CEO & Director
  • Mr. Paul Connolly (Age 54)
    Pres of Global Operations
  • Mr. Andrew Swift
    VP of Investor Relations
  • Ms. Helen Barraclough (Age 43)
    Group Gen. Counsel, Company Sec. & Director
  • Ms. Alison Parkes (Age 50)
    Chief Compliance Officer
  • Mr. Joe Metzger
    Sr. VP of Marketing Services & Communications
  • Ms. Elga Lohler (Age 54)
    Chief HR Officer
  • Mr. Philip G. Cowdy (Age 55)
    Chief Bus. Devel. & Corp. Affairs Officer
  • Mr. Bradley Cannon (Age 54)
    Pres of Orthopaedics, Sports Medicine & ENT and Americas













SNN Stock - Frequently Asked Questions

Should I buy or sell Smith & Nephew stock right now?

7 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Smith & Nephew in the last year. There are currently 4 hold ratings and 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "hold" SNN shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in SNN, but not buy additional shares or sell existing shares.
View SNN analyst ratings
or view top-rated stocks.

How have SNN shares performed in 2022?

Smith & Nephew's stock was trading at $34.62 at the start of the year. Since then, SNN stock has decreased by 34.6% and is now trading at $22.63.
View the best growth stocks for 2022 here
.

Are investors shorting Smith & Nephew?

Smith & Nephew saw a increase in short interest in the month of September. As of September 15th, there was short interest totaling 3,770,000 shares, an increase of 62.5% from the August 31st total of 2,320,000 shares. Based on an average daily volume of 1,210,000 shares, the short-interest ratio is presently 3.1 days. Approximately 0.9% of the company's shares are short sold.
View Smith & Nephew's Short Interest
.

How were Smith & Nephew's earnings last quarter?

Smith & Nephew plc (NYSE:SNN) issued its earnings results on Monday, November, 17th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts' consensus estimates of $0.39 by $0.59.

How often does Smith & Nephew pay dividends? What is the dividend yield for Smith & Nephew?

Smith & Nephew announced a semi-annual dividend on Monday, August 1st. Stockholders of record on Friday, September 30th will be paid a dividend of $0.288 per share on Wednesday, October 26th. This represents a yield of 2.8%. The ex-dividend date of this dividend is Thursday, September 29th.
Read our dividend analysis for SNN
.

Is Smith & Nephew a good dividend stock?

Smith & Nephew (NYSE:SNN) pays an annual dividend of $0.90 per share and currently has a dividend yield of 4.10%. SNN has a dividend yield higher than 75% of all dividend-paying stocks, making it a leading dividend payer.
Read our dividend analysis for SNN.

What other stocks do shareholders of Smith & Nephew own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Smith & Nephew investors own include Smith & Nephew (SN), RPM International (RPM), Gilead Sciences (GILD), AbbVie (ABBV), Alibaba Group (BABA), Johnson & Johnson (JNJ), Pfizer (PFE), Abbott Laboratories (ABT), Alexion Pharmaceuticals (ALXN) and Amgen (AMGN).

What is Smith & Nephew's stock symbol?

Smith & Nephew trades on the New York Stock Exchange (NYSE) under the ticker symbol "SNN."

Who are Smith & Nephew's major shareholders?

Smith & Nephew's stock is owned by many different retail and institutional investors. Top institutional investors include Nuance Investments LLC (2.51%), Lazard Asset Management LLC (0.36%), Wells Fargo & Company MN (0.22%), JPMorgan Chase & Co. (0.12%), FMR LLC (0.11%) and Goldman Sachs Group Inc. (0.09%).

How do I buy shares of Smith & Nephew?

Shares of SNN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Smith & Nephew's stock price today?

One share of SNN stock can currently be purchased for approximately $22.63.

How much money does Smith & Nephew make?

Smith & Nephew (NYSE:SNN) has a market capitalization of $9.85 billion and generates $5.21 billion in revenue each year.

How many employees does Smith & Nephew have?

The company employs 18,000 workers across the globe.

How can I contact Smith & Nephew?

Smith & Nephew's mailing address is BUILDING 5 CROXLEY PARK HATTERS LANE, WATFORD X0, WD18 8YE. The official website for the company is www.smith-nephew.com. The medical equipment provider can be reached via phone at 441923477100, via email at andrew.swift@smith-nephew.com, or via fax at 44-20-7930-3353.

This page (NYSE:SNN) was last updated on 9/29/2022 by MarketBeat.com Staff

MarketBeat Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here
MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

MarketBeat is accredited by the Better Business Bureau MarketBeat is rated as Great on TrustPilot

© American Consumer News, LLC dba MarketBeat® 2010-2022. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | contact@marketbeat.com | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Privacy Policy | Do Not Sell My Information | RSS Feeds

© 2022 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see Barchart's disclaimer.